Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H13ClF3N3O2 |
| Molecular Weight | 395.763 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=C(C)NC(=N[C@H]1C2=CC=C(F)C=C2Cl)C3=NC=C(F)C=C3F
InChI
InChIKey=FVNJBPMQWSIGJK-HNNXBMFYSA-N
InChI=1S/C18H13ClF3N3O2/c1-8-14(18(26)27-2)15(11-4-3-9(20)5-12(11)19)25-17(24-8)16-13(22)6-10(21)7-23-16/h3-7,15H,1-2H3,(H,24,25)/t15-/m0/s1
| Molecular Formula | C18H13ClF3N3O2 |
| Molecular Weight | 395.763 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
BAY 41-4109 (methyl (R)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-pyrimidine-5-carboxylate) is a heteroaryldihydropyrimidine (HAP) antiviral compound. BAY 41-4109 treatment disassembled the core capsids and separated them into monomers or dimers, the form in which they could be further degraded into peptides. The core protein assembled in a misdirected manner cannot function effectively. BAY 41-4109 was effective in animal models of HBV, however, its development was discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. | 2002 May |
|
| BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. | 2006 Nov-Dec |
|
| NMR-spectroscopy-based metabonomic approach to the analysis of Bay41-4109, a novel anti-HBV compound, induced hepatotoxicity in rats. | 2007 Sep 28 |
|
| Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor. | 2015 Nov 30 |
Patents
Sample Use Guides
BAY 41-4109 was investigated in HBV-transgenic mice (Tg [HBV1.3 fsX(-)3'5']). Bay 41-4109 was administered per os using different schedules (b.i.d. or t.i.d. for up to 28 days) and dosages ranging from 3 to 30 mg/kg. The compound reduced viral DNA in the liver and in the plasma dose-dependently.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:17:41 UTC 2023
by
admin
on
Sat Dec 16 09:17:41 UTC 2023
|
| Record UNII |
M862I4T61O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
M862I4T61O
Created by
admin on Sat Dec 16 09:17:41 UTC 2023 , Edited by admin on Sat Dec 16 09:17:41 UTC 2023
|
PRIMARY | |||
|
489221
Created by
admin on Sat Dec 16 09:17:41 UTC 2023 , Edited by admin on Sat Dec 16 09:17:41 UTC 2023
|
PRIMARY | |||
|
DTXSID401107166
Created by
admin on Sat Dec 16 09:17:41 UTC 2023 , Edited by admin on Sat Dec 16 09:17:41 UTC 2023
|
PRIMARY | |||
|
298708-81-3
Created by
admin on Sat Dec 16 09:17:41 UTC 2023 , Edited by admin on Sat Dec 16 09:17:41 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
Inhibits capsid assembly
|
||
|
TARGET->INHIBITOR OF AGGREGATION |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
